As we know Genzyme has become a leader in biotechnology ranking in around $4 billion in revenues last year. The company managed to create a competitive advantage in an industry that has been struggling to keep up with innovations and still be profitable. One of the reasons for such success in the pharmaceutical industry is the ability of this company to gain share in the global market while keeping its core values unchanged. The focus of the company from the beginning has been putting patients first and the focus on the “two-price policy” – full price or free for patients in need and who could not afford it. HAND was created to help an untapped market, where neglected diseases such as tuberculosis kill as much as 2 million people a year in
…show more content…
An initiative by Brazilian doctor Rogerio Vivaldi, senior vice president and head of Latin American operations. This is a very important project for Genzyme in Brazil. Fiocruz, a government sponsored organization has long been seeking a partner to help research on Chagas disease move forward. This disease is mostly predominant in Mexico, Central and South America, affecting approximately 18 million people a year and killing 50,000 a year. Transmission is through a bug that comes out at night to bite and infect victims. Strategically speaking, Chagas would be a good project to take on and create roots in Brazil, but it is a market that could not be scaled. It is a very limited and small market for HAND. Finally, Tuberculosis a highly infectious disease, affecting most developing countries and killing more than 1.5 million people a year. It is spread through air by infected people coughing, sneezing or spitting. Besides the alarming numbers, pharma industry and non-government agencies have yet to dedicate time in researching a vaccine/cure for TB. Currently there is a treatment comprised of four drugs developed in the sixties. The treatment is expensive and it takes up to six months. Treatment is mostly never completed and this fueled the rise of XDR-TB, a drug-resistant form of the
An initiative by Brazilian doctor Rogerio Vivaldi, senior vice president and head of Latin American operations. This is a very important project for Genzyme in Brazil. Fiocruz, a government sponsored organization has long been seeking a partner to help research on Chagas disease move forward. This disease is mostly predominant in Mexico, Central and South America, affecting approximately 18 million people a year and killing 50,000 a year. Transmission is through a bug that comes out at night to bite and infect victims. Strategically speaking, Chagas would be a good project to take on and create roots in Brazil, but it is a market that could not be scaled. It is a very limited and small market for HAND. Finally, Tuberculosis a highly infectious disease, affecting most developing countries and killing more than 1.5 million people a year. It is spread through air by infected people coughing, sneezing or spitting. Besides the alarming numbers, pharma industry and non-government agencies have yet to dedicate time in researching a vaccine/cure for TB. Currently there is a treatment comprised of four drugs developed in the sixties. The treatment is expensive and it takes up to six months. Treatment is mostly never completed and this fueled the rise of XDR-TB, a drug-resistant form of the